We're rapidly approaching the end of 2012 and, while initial public offerings for tech companies usually grab the headlines, the health care space also had a number of exciting IPOs this year. Not all of them were winners, but Tesaro is up more than 16% year to date (as of the writing of this article). In the following video, health care analysts Max Macaluso and Brenton Flynn discuss Tesaro's business and drug pipeline.
For nearly 100 years, Merck's cutting-edge research has led to a number of medical breakthroughs. Today, however, this pharma stalwart is staring down a steep patent cliff and facing generic competition for its top-selling drug. Will Merck crumble under its own weight, or will it continue to pay dividends to investors for another century? To find out if this pharma giant has the stamina to keep its Bunsen burners alight, grab your copy of our brand new premium research report today. Our senior biotech analyst Brian Orelli, Ph.D., walks you through both the opportunities and threats facing Merck, and the report comes with a full 12 months of updates. Claim your copy now by clicking here.
The article 2012 in Review: Tesaro originally appeared on Fool.com.
Brenton Flynn, Max Macaluso, Ph.D., and The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.